Key result
Intravenous infusion of AZD1305 dose-dependently increased the left atrial effective refractory period, with a mean increase of 55 milliseconds in dose group 3.
Why the study?
Does intravenous AZD1305 alter cardiac electrophysiological and hemodynamic parameters in patients after catheter ablation of atrial flutter?
Population
50 patients after successful catheter ablation of atrial flutter
Comparison
Intravenous infusion of the combined ion channel… vs Placebo
Design
RCT, randomized
Follow-up
20 minutes after start of infusion
Authors
Loading...
May support AZD1305 development for atrial fibrillation rhythm control; extends ERP prolongation data to post-ablation patients.
RCT (n=50)
Does intravenous AZD1305 alter cardiac electrophysiological and hemodynamic parameters in patients after catheter ablation of atrial flutter?
Mean Difference: 55
Intravenous AZD1305 dose-dependently increases atrial and ventricular effective refractory periods without proarrhythmia, suggesting potential antiarrhythmic efficacy for atrial fibrillation.
Toivonen et al. (2010) conducted an RCT in Atrial flutter (n=50). AZD1305 vs. Placebo was evaluated on Left atrial effective refractory period (mean increase of 55 milliseconds). Intravenous infusion of AZD1305 dose-dependently increased the left atrial effective refractory period, with a mean increase of 55 milliseconds in dose group 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: